FDA reiterates guidance plans on distributed and point-of-care manufacturing (from Catapult’s regulatory round-up – November 2023)
The FDA has reiterated its plan to issue draft guidance spelling out how it intends to regulate distributed manufacturing (DM) and point-of-care (POC) manufacturing of drugs and biologics. FDA expects that issuing such guidance may...